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Abstract
Computational models that forecast the progression of Alzheimer’s disease at the patient
level are extremely useful tools for identifying high risk cohorts for early intervention and
treatment planning. The state-of-the-art work in this area proposes models that forecast
by using latent representations extracted from the longitudinal data across multiple modal-
ities, including volumetric information extracted from medical scans and demographic info.
These models incorporate the time horizon, which is the amount of time between the last
recorded visit and the future visit, by directly concatenating a representation of it to the
latent data representation. In this paper, we present a model which generates a sequence
of latent representations of the patient status across the time horizon, providing more in-
formative modeling of the temporal relationships between the patient’s history and future
visits. Our proposed model outperforms the baseline in terms of forecasting accuracy and
F1 score.
1. Introduction
Longitudinal medical datasets commonly contain biomarker information and medical scans
spanning multiple years for thousands of patients. Recently, there has been an increased
interest in building deep learning models, which have the benefit of being able to extract
relevant features from datasets without expert knowledge, to forecast a patient’s disease
progression. If effective, such models have the potential to become extremely useful tools
for identifying high risk cohorts for early intervention and treatment planning.
Clinical Relevance With the increase in the world’s aging population, dementia is a
critical threat to health around the world. Currently, it is estimated that 24 million people
world wide suffer from the condition and this number is projected to double every 20 years
(Reitz et al., 2011). Alzheimer’s disease is one of the most prevalent forms of dementia.
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Diagnosis of Alzheimer’s takes into account many factors such as performance on cognitive
screens, inheritance of high-risk biomarkers, and assessment of MRI scans (Neugroschl and
Wang, 2011). Deep learning models that can leverage signals from these varying factors in
order to accurately forecast the progression of the disease would greatly benefit doctors in
identifying patients that are at a high risk of developing Alzheimer’s.
Technical Significance A wide range of models using deep learning to forecast longi-
tudinal signals have been proposed in the literature. These approaches can be generalized
as follows: they project the inputs collected from patient history into a common space us-
ing some fully-connected layers and then send the projected representations to a sequence
learning model such as an RNN. The time horizon τ , which is the interval between the last
observed status and the predicted status, is concatenated to the output of the RNN and
sent to a classifier which assigns a disease stage label to the patient, τ time steps into the
future.
These techniques do not take advantage of a temporal structure of a patient’s historical
information. By simply concatenating τ to the output of the RNN, the models are not taking
temporal information into account when forecasting the visit that occurs τ time steps into the
future. In this case, τ is an additive term which signals the magnitude of the time horizon to
the classifier without much of an effect on the overall prediction. Thus, the resulting model
is partially agnostic with respect to the temporal correlations that occur across the time
horizon. Additionally, with these methods, the irregular time intervals between consecutive
visits are not incorporated into the model at any stage in the training process, resulting
in models which operate under the assumption that the visits in all sequences are spaced
uniformly in time.
To address these problems, we propose FLARe: Forecasting by Learning Anticipated
Representations, a generative model which naturally incorporates τ into the prediction
pipeline with the ability to "impute" representations of missing visits. FLARe draws inspi-
ration from language modeling (LM), which is one of the most widely researched areas in
natural language processing. One of the key challenges in LM is to come up with models
that can generate sentences or paragraphs of any language. This is typically done by training
a model to sequentially generate the next word, given a history of generated words. Such
models are trained by optimizing the loss obtained by aggregating the difference between
the predicted next word and the actual next word in each sentence in the training data.
This approach operates under the assumption that every language has constraints on the
ordering of words in a sentence. The model tries to learn what the most probable words are,
given the present word or the history of words.
In FLARe, we follow a similar intuition by operating under the assumption that there
are constraints on how much the 3D MRI scans and cognitive tests of a given patient can
vary within 1 time point – which corresponds to 6 months. It follows from these assumptions
that we should be able to train a model that can sequentially predict the feature vector of
the patient in the next time step, given his/her feature vector in the present time step as
well as the complete history until that point. Furthermore, we can do this by minimizing the
loss obtained by aggregating the differences in the predicted and actual values of the next
feature vector. As a byproduct of this sequence generation approach, our proposed model
can also robustly handle patient trajectories which contain missing visits by ’imputing’ their
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learned representations. All of these factors together give FLARe a heightened ability to
model the temporal relationship between a patient’s medical history and their future health
status, resulting in better disease stage forecasting accuracy.
We tested our proposed model on the data of 1652 patients from the publicly available
ADNI (Alzheimer’s Disease Neuroimaging Initiative) dataset using volumetric information
extracted from MRI scans along with demographic information and cognitive test scores as
input features. Our results show that our proposed model outperforms baseline models in
terms of forecasting performance, while providing more balanced predictions across disease
classes. We provide detailed analysis of the performance of our model over different time
horizons τ and time steps T used for forecasting.
2. Related Work
Disease progression modeling has been an important topic in the field of healthcare analytics.
Existing work in this area has been applied towards the development of early prevention
and treatment methods. Ito et al. (2010) develop a progression model based on data from
literature in order to measure longitudinal changes in cognitive test scores of Alzheimer’s
patients. De Winter et al. (2006) propose a progression model for Type 2 Diabetes that aims
to identify the effects of various treatments on diabetes-related biomarkers. There has also
been much previous work in joint modeling, which is the sharing of parameters between two
submodels: one for longitudinal outcomes and another for time-to-event outcomes Hickey
et al. (2016) in order to jointly forecast the two. However, the aforementioned models require
medical domain knowledge of the pathologies of the diseases being modeled and thus must
be modified for use on different diseases.
Recently, there has been increased interest in disease progression modeling in the ma-
chine learning community. Such approaches attempt to model the trajectory of the disease
using statistical and machine learning techniques on observational data acquired from med-
ical records. A variety of methods have been deployed for the task including Markov Jump
Models (Wang et al., 2014), Gaussian Processes (Schulam and Arora, 2016), and Functional
Clustering (Yao et al., 2005), (Halilaj et al., 2018). Some approaches such as Sukkar et al.
(2012) propose models which identify more fine grained trajectory types outside of the stan-
dard clinical stages and explore the correlations between multiple longitudinally collected
measurements. Zhou et al. (2012) approach the problem by treating it as a multi-task regres-
sion, where the objective is to jointly model the trajectory of multiple longitudinal outcomes
and biomarkers.
Even more recently, deep learning approaches to the problem have experienced increasing
popularity due to their ability to learn features from the dataset without the need for
domain knowledge. Fiterau et al. (2017) use hybrid CNN and LSTM layers which leverage
information from structured covariates to predict the cartilage degeneration of patients with
osteoarthritis, six years into the future. Bhagwat et al. (2018) use a Siamese network to
learn a difference representation between two visits in a patient’s history in order to classify
the patient’s trajectory into hierarchically clustered classes. Both Choi et al. (2016) and Lim
and van der Schaar (2018) treat the disease progression as a slowly evolving point process
and use temporal deep learning models such as RNNs to jointly model event occurrences and
doctor diagnosis although the former directly predict the time-to-event occurrence and ICU-
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9 codes of patients while the later predict the parameters of time-to-event and longitudinal
measurement distributions.
3. Methodology
3.1. Model Description
Let Xtraj = [xv1 ,xv2 , ...,xvL ] = xv1:vL denote the trajectory of a patient where v1 < v2 <
v3 < ... < vL and xvt are the input features from some patient at visit t. Note that
v1, v2, . . . vL ∈ N and do not have to be consecutive. However, we can assume that they are
without loss of generality.
Our goal is to predict the disease stage of the patient at visit vL+τ where τ ∈ N.
We let xvt = ivt⊕svt⊕cvt where ivt , svt , cvt denote volumetric information, demographic
information, and cognitive test scores respectively, where ⊕ is concatenation.
First, we use three seperate multilayer perceptrons, φi, φs, φc, one for each category of
input features to encode our input features into a common latent space. After we extract
the representations, we concatenate them:
φi,s,c(xvt) = φi(ivt)⊕ φs(svt)⊕ φc(cvt) = fvt
We do this for all xvt ∈Xtraj resulting in:
φ(Xtraj) = fv1:vL
Then, the sequence fv1:vL is sent to an RNN which provides hidden layer outputs for
each input:
RNN [fv1:vL ] = hv1:vL
Each entry is used as input to another MLP, which we refer to as the feature prediction
network, ρ(.). The purpose of ρ(.) is to take the hidden layer output hvL and reconstruct
the latent representation of xvL+1 that is generated by φ(.). More generally:
ρ(hvt) = fˆvt+1, t ∈ N
fˆvL+1 is the reconstructed latent representation of a patient’s disease progression at visit
vL + 1. We create an auxiliary loss term Laux(fvL+1, fˆvL+1), which is the mean squared
error between the reconstructed representations and the learned representations of the visit
data that we have available.
At this stage, we have dealt with all of the available visit data in the trajectory. If the
trajectory only consisted of one visit, say Xtraj = xv1 , we would skip the RNN and take the
representation fv1 and send it through ρ resulting in ρ(fv1) = fˆv1+1. Then classifier(fˆv1+1)
is the disease progression prediction of the patient at time v1+1. Otherwise, in the general
case where we have more than one visit we have this chain of events:
fˆvL+1 → RNN [.]→ hˆvL+1 → ρ(.)→ fˆvL+2 → . . .
We continue iteratively generating the sequence of representations for the datapoints
between our last available visit vL and the visit we want to forecast vL + τ until we reach
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hˆvL+τ . Finally, we take classifier(hˆvL+τ ) to be the disease stage forecast of the patient
at time vL + τ . The disease stage of the patient can be placed in three categories: Cogni-
tively Normal (CN), Mild Cognitive Impairment (MCI), or Alzheimer’s Disease (AD). If the
trajectory is not continuous, i.e v1, v2, ..., vL are not consecutive, we can use ρ to "impute"
any missing representation. During training, we backpropagate on both cross entropy loss,
Lcel and an auxiliary loss Laux. For this paper, we let the auxiliary loss to be the mean
squared error between the forecasting feature vector and the ground truth feature vector
although it would also be plausible to use the cross-entropy loss from labels predicted from
the forecasted feature vectors. The objective function for a batch of N training samples is
given in equation (1). The diagrams of FLARe and the baseline model are illustrated in
Figure 1.
L =
N∑
n=1
−yn log(softmax(yˆn))︸ ︷︷ ︸
Lcel
+α
N∑
n=1
MSE(fˆn,fn)︸ ︷︷ ︸
Laux
(1)
(a)
(b)
Figure 1: Diagrams illustrating the structure of the baseline (a) and FLARe (b)
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4. Experiments
4.1. Dataset
We used the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 1 dataset for our exper-
iments. The ADNI dataset contains clinical information and biomarkers taken from 2104
patients during visits that occur every 6 months spanning over five years. The dataset
contains 1907 metrics recorded from the patient during each visit although it is common
for many entries to be missing, and the patterns of missingness to be inconsistent across
patients.
Subjects are given a diagnostic label of Cognitively Normal (CN), Mild Cognitive Im-
pairment (MCI), and Alzheimer’s Disease (AD) during each visit. For more detailed infor-
mation, the class breakdown and the number of disease stage transitions are available in
Appendix ??.
In addition to undergoing a cranial MRI scan, patients have a variety of other metrics
recorded during each visit including real-valued bio-markers that measure atrophy, molecular
processes, and protein levels of a patient. These bio-markers include PET scans, Cerebral
Spinal Fluid (CSF) measures, and volumetric measures extracted from MRI scans using
FreeSurfer segmentation software. Additionally, patients take up to seven cognitive tests
such as Alzheimer’s Disease Assessment Scale-Cognitive 13 Item Scale (ADAS-Cog13) and
MMSE (Mini Mental State Examination) during each visit as a measure of their cognitive
ability. Demographic information such as age, sex, and weight, along with risk factors such
as presence of the APOE-4 gene are also recorded.
A list of patient IDs we used for training and testing will be made available in our code
repository.
4.2. Experimental Setting
We shuffled the training data and performed an 80/20 split across 1652 patients. To address
the class imbalance within our dataset, we used a weighted Cross Entropy Loss based on
the class proportions. A list of hyperparameters we used for both models is available in
Appendix C.
We chose 697 features from the ADNI dataset. 692 of them were volumetric measures
taken from the segmentation of MRI scans, 4 were cognitive test scores, and 3 were demo-
graphic information. A detailed list of the features used will be made available in the code
repository since the entire list is too long to put in this submission.
In order to create more training examples for our model, we generate multiple samples
from a given patient trajectory Xtraj . We set two sampling parameters: T , which is the
number of points used for prediction and τ , the time horizon. For example, let Xtraj =
[xv1 ,xv2 ,xv3 ,xv4 ]. If we are sampling subtrajectories for T = 2 for τ = 1, we would have:
[xv1 ,xv2 ] and [xv2 ,xv3 ] where the disease stage of xv3 and xv4 would be the labels for each
sampled trajectory respectively.
For the ADNI dataset, each unit of τ is 6 months. For each patient trajectory in a
training batch, our model samples data for every possible value T and τ . We made the
decision to avoid sampling for T = 1 since we wanted to use a sequence based model.
1. www.adni.loni.usc.edu
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Number of Patients Augmented Trajectories
Training 1321 21520
Testing 331 5533
Table 1: Number of patients used for training and testing along with the number of trajectories
augmented from them
Since the lengths of the trajectories ranged from 2 to 4 and thus did not exhibit enough
range to be high variance, we decided to train our model on batches which contained tra-
jectories of the same length, as opposed to using the common NLP technique of padding a
batch of variable length sequences to be the same length. To select which trajectory length
to load into a batch, we randomly sampled the trajectory length from a uniform distribu-
tion. We found that our results were sensitive to the method of loading the batches, but
still resulted in models that supported the conclusion of our original experiments. Results
for both dataloading approaches are available in the results section. 2
Subsampling from our training data exposes our model to more trajectories of varying
time horizons and points used for prediction. We split the patients into training and test
sets before sampling so that samples generated for one patient will only be encountered in
the training set. For our test set, we perform the same augmentation routine on the test
sample. Table 1 illustrates the number of patients we used for training and testing, along
with the total number of trajectories we sample from each set:
4.3. Architecture Selection
In order to determine the architecture for the initial MLP φ, we chose the architecture
that performed the best on disease stage classification. This way, we could ensure that
the architecture for φ is capable of extracting informative representations from the training
data. Detailed descriptions of the model architectures will be made available in the code
repository.
4.4. Candidate Models
We compare the performance of FLARe against the baseline model RNN-Concat, which is
a reimplementation of current forecasting models. It concatenates the time horizon τ to
the hidden layer output of the RNN. We keep the model architectures the same between
FLARe and RNN-Concat in order to control against the slight performance variations that
may occur when implementing different architectures.
4.5. Results
Table 2 contains the classification accuracy, precision, recall, and F1-scores of the models we
tested using the random batch loading approach. We found that FLARe outperforms RNN-
Concat across all the evaluation metrics. Additionally, we observe that while the baseline
has unbalanced performance across disease stages, often predicting MCI stage patients as
2. Link to code used to run experiments is available at https://github.com/Information-Fusion-Lab-
Umass/flare/tree/legacy
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Accuracy Precision Recall F1 score
RNN-Concat .603 .607 .610 .609
FLARe .659 .670 .660 .665
Table 2: Results for Alzheimer’s disease stage forecasting
AD or NC, our model provides more balance between the classes. Confusion matrices for
RNN-Concat and FLARe are provided in Table 3 and Table 4 to illustrate the difference in
class balance between models.
True
Predicted
NL MCI AD
NL 0.65 0.19 0.16
MCI 0.30 0.40 0.30
AD 0.14 0.08 0.78
Table 3: Average confusion matrix obtained
across all possible values of (T, τ) using RNN-
Concat
True
Predicted
NL MCI AD
NL 0.66 0.23 0.11
MCI 0.19 0.71 0.10
AD 0.13 0.26 0.61
Table 4: Average confusion matrix obtained
across all possible values of (T, τ) using FLARe
To analyze our proposed model’s change in performance across different levels of data
availability and forecasting horizons, we partition the testing set into buckets where each
bucket corresponds to an ordered pair (T, τ): the number of points used for prediction and
the forecasting horizon. In Table 5 and Table 6, we provide the F1 score of RNN-Concat
and FLARe for each bucket. Since our results vary with the batch loading approach used,
we provide the table of results for two batch loading schemes we tried. In the first one,
we randomly sample the sequence length from a uniform distribution and emit a batch of
that sequence length. In Table 6, we keep a Dataloader for each sequence length and iterate
through each of them during an epoch. We can make the following observations from the
tables:
• FLARe is consistently on par or better than RNN-Concat across all buckets of the
partitioned test set.
• The F1-scores of FLARe improve as the number of available visits increases. This is
expected since the model has more data to make a prediction about the future visit
representation.
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6 months 12 months 18 months
2 visits Concat: .7334FLARe: .7152
Concat: .5268
FLARe: .6272
Concat: .5468
FLARe: .6433
3 visits Concat: .6183FLARe: .7486
Concat: .5995
FLARe: .7442 N/A
4 visits Concat: .7494FLARe: .7957 N/A N/A
Table 5: F1 scores of Alzheimer’s disease stage forecasting over each bucket of the partitioned test
set using our random batch loading approach.
6 months 12 months 18 months
2 visits Concat: .5454FLARe: .8399
Concat: .4978
FLARe: .8425
Concat: .3895
FLARe: .8208
3 visits Concat: .7436FLARe: .8674
Concat: .7542
FLARe: .8134 N/A
4 visits Concat: .7172FLARe: .8729 N/A N/A
Table 6: F1 scores of Alzheimer’s disease stage forecasting over each bucket of the partitioned test
set using pytorch’s built-in DataLoader class. Model parameters are determined by using the weights
from the epoch with the lowest training loss. Notice how the inclusion of the built-in Dataloader
increases FLARe’s performance by a huge margin across all buckets, while Concat’s performance
increases in some buckets and decreases in others when compared to the results in Table 5.
5. Conclusion
In this paper, we present a novel approach called FLARe for disease trajectory forecasting
using multimodal longitudinal data. FLARe uses a feature prediction module to anticipate
the learned representations of the sequence of visits leading up to the future visit, given
the representations of the history of visits, instead of directly concatenating some represen-
tation of the forecasting horizon τ to a latent representation of the medical history of the
patient. The main reason why FLARe is so effective is because it has the capacity to model
a more descriptive temporal relationship between a patient’s medical history and their fu-
ture health status. Also, FLARe has an inherent robustness towards missing data, as it is
trained to learn representations that can be used to impute the missing data points. Our
performance analysis over the partitioned test set serves to illustrate this point. We observed
that generally as the number of visits used for prediction increases, FLARe consistently has
a better, or on par, F1 score across all time horizons when compared to the baseline model
of RNN-Concat.
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Appendix A: Transitions and Disease Stage Counts in Experiment Data
Table 7: Disease Stage Counts
Number of Patients
Cognitively Normal (CN) 805
Mild Cognitive Impairment (MCI) 536
Alzheimer’s Disease (AD) 317
Table 8: Transition Counts
Number of Transitions
CN to MCI 66
MCI to AD 318
CN to AD 2
Appendix B: Number of Trajectories Used Per Partition
Table 9: Breakdown of number of samples in each partition of the training set
6 months 12 months 18 months 24 months
2 visits 2954 2079 1294 N/A
3 visits 1982 1227 N/A N/A
4 visits 1165 N/A N/A N/A
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Table 10: Breakdown of number of samples in each partition of the testing set
6 months 12 months 18 months 24 months
2 visits 762 536 332 N/A
3 visits 514 317 N/A N/A
4 visits 301 N/A N/A N/A
Appendix C: Hyperparameters
Class Weights Learning Rate Optimizer Epochs Total
Hyperparameters [CN:1,MCI:1.3,AD:2] .001 ADAM 10000
12
